Business, energy, technology, markets and global industry news from Business News Today

hepatitis B virus

PharmaDeviceNews hepatitis B virus
AusperBio’s AHB-171 clinical study marks the first patient dosing of its investigational liver-targeted siRNA candidate for chronic hepatitis B, expanding the company’s pursuit of a functional HBV cure. Representative image.
Pharma & Biotech

AusperBio has entered the HBV siRNA race, but can AHB-171 move beyond antigen suppression?

AusperBio has dosed the first patient with AHB-171, testing a liver-targeted siRNA candidate and a broader combination strategy for hepatitis B.

Read More
Representative image: Laboratory researchers handle blood samples during chronic hepatitis B drug development, reflecting Brii Bio’s Phase 2b ENRICH and ENHANCE results for BRII-179, elebsiran and pegylated interferon alfa.
Pharma & Biotech

Why Brii Bio’s BRII-179 sequencing data could reshape hepatitis B combination treatment

See how Brii Bio’s Phase 2b hepatitis B data support BRII-179 immune priming while durability and Phase 3 risks remain.

Read More